This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1254 entries already.
In order to incentivise drug companies to re-enter development of antibiotics, the UK government announced it will establish a licence model to assure developers sufficient return on investments (ROI).
Immunoncology and vaccine specialist BioNTech AG is broadening its antibody discovery capabilities by acquiring MAB Discoverys antibody generation unit.
Swiss fine chemicals specialist Clariant has hammered out a R&D pact with ExxonMobil and Renewable Energy Group (REG) Inc to combine technologies in order of producing biodiesel from cellulose
The Innovative Medicines Initiative II has earmarked 80m for pre-competetive research improving the pharmaceutical industry’s productivity.
Novo Holdings has invested 18m from its 135m REPAIR Impact Fund into four companies.
Boehringer Ingelheim has expanded its 2014 R&D collaboration with the BioMed X Innovation Center (Heidelberg, Germany) to find new treatment approaches for early intervention of psychiatric diseases.
Canadian and Finnish researchers have demonstrated that long immune cell contact to lung tissue turns tissue repair into fibrosis.
French vaccine specialist Valneva SE has inked a supply contract with the US Department of Defense for IXIARO its Japanese encephalitis (JE).
Researchers at VTT Technical Research Centre of Finland Ltd have presented a new gasification-based technique to turn forest industry byproducts into transport fuels and chemicals.
German researchers have modeled when cellular alterations inevitably lead to the development of cancer. The transition is tissue-specific and needs only a few cells.